TRACIE / CO-AU-979-6695
TRodelvy use in AdvanCed TrIple Negative BrEast Cancer in Australia
Trial summary:
This is a secondary data use non-interventional study of patients in Australia who received Sacituzumab govitecan (Trodelvy), for the treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Receptor status / problem studied:
Inclusion criteria
1) Patients with metastatic, or inoperable, locally advanced TNBC (either relapsed or de novo metastatic).
2) Patients who started SG during the patient identification period according to the locally approved indication: “Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received at least two prior systemic therapies, including at least one prior therapy for locally advanced or metastatic disease”.
Exclusion criteria
1) Patients participating in any interventional clinical trials during SG treatment.
2) History of SG use prior to first administration for advanced TNBC.
Trial Title
TRACIE / CO-AU-979-6695
Diagnosis
Breast cancer
Type of trial
Collaborative
Type of treatement
Medical Oncology
Phase
Registry